Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | HK1 | P19367 | 1/20 | 0.35 |
| ▸ | HK2 | P52789 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20953447 | 0.87 | CFTR (0.41) | LGALS3MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL20953434 | 0.87 | MAPK13 (0.50) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL16946211 | 0.84 | TSHR (0.44) | LGALS3 | |
| SCHEMBL16941671 | 0.84 | TSHR (0.44) | LGALS3 | |
| SCHEMBL15436011 | 0.84 | TSHR (0.44) | LGALS3 | |
| SCHEMBL15436010 | 0.84 | TSHR (0.44) | LGALS3 | |
| SCHEMBL15445169 | 0.84 | TSHR (0.44) | LGALS3 | |
| SCHEMBL20953462 | 0.82 | MAPK13 (0.35) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL20953449 | 0.82 | LGALS9 (0.41) | LGALS3MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL20953419 | 0.79 | ABL1 (0.36) | MAPK13MAPK12MAPK11MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273313-B2 | Multimeric mannosides, a process for preparing the same and their uses as a drug | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273313-B2 | Multimeric mannosides, a process for preparing the same and their uses as a drug | MANBA, MAN2A1, MAN2B2 | LGALS3 114/4885MAPK13 1552/4885MAPK12 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.